StockTipsArenaBeta

BUY Sun Pharmaceutical Industries Ltd. — Arpit Beriwal, Motilal Oswal

BUYSun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries share price target & all analyst calls

byArpit Beriwal, Motilal OswalHorizon: 1–3 months30 Jul 2026via ET Now

Entry₹2,016.4Inferred
Target₹2,100
Total upside +4.15% (call closed)
Stop lossNot given
At expiry₹1,777.730 Oct 2026, 3:30 pm
Expired-11.84%auction close
Follow Arpit Beriwal for new callsGet alertsWatch SUNPHARMA for new buy/sell callsGet alertsSee 75 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Oct, 9:25 pm IST
11 supporting8 neutral2 opposing
Supports the BUY call (11)

Sun Pharma shares extend 4-day rally after USFDA approval for ILUMYA in arthritis patients

NewsCnbc-Tv18·30 Oct · today

(opens in new tab)

Sun Pharma received U.S. FDA approval for ILUMYA (tildrakizumab-asmm) to treat adults with active Psoriatic Arthritis, expanding the drug's market reach.

BSE · Company Update·30 Oct · today

(opens in new tab)

14 advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·30 Oct · today

Sun Pharma's drug UNLOXCYT (cosibelimab-ipdl) received a Category 2A preferred designation in the updated NCCN guidelines for locally advanced cutaneous squamous cell carcinoma.

NSE · Press Release·20 Oct · 1w ago

(opens in new tab)

Sun Pharma's drug UNLOXCYT (cosibelimab-ipdl) has been elevated to a Category 2A preferred designation in the NCCN Guidelines for locally advanced cutaneous squamous cell carcinoma (laCSCC).

BSE · Company Update·20 Oct · 1w ago

(opens in new tab)
Neutral / worth noting (8)

Unaudited Financial Results for the quarter and half year ended 30 September 2026

NSE · Outcome of Board Meeting·30 Oct · today

(opens in new tab)

Sun Pharma to raise Rs 10,000 crore to part-finance Organon deal

NewsEt-Markets·21 Oct · 1w ago

(opens in new tab)

Pharma Q2 Outlook: Pricing pressure, US competition to weigh on select players

NewsEt-Markets·19 Oct · 2w ago

(opens in new tab)

CRISIL and ICRA have assigned ratings to the company's proposed non-convertible debenture programme and reaffirmed ratings on existing bank facilities and commercial paper.

BSE · Company Update·13 Oct · 2w ago

(opens in new tab)

Sun Pharma to consider ₹15,000 crore NCD issue; board meeting on 12 October

NewsLivemint·7 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Sun Pharmaceutical Industries

All analyst calls on Sun Pharmaceutical Industries

More from Arpit Beriwal, Motilal Oswal

Every call and its outcome